Radiological evaluation of newly diagnosed non-brainstem pediatric high-grade glioma in the HERBY phase II trial.
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Rodriguez Gutierrez D
- Jones C
- Varlet P
- Mackay A
- Warren D
- Warmuth-Metz M
- Sánchez Aliaga E
- Calmon R
- Hargrave DR
- Massimino M
- Azizi AA
- Le Deley MC
- Saran F
- Rousseau RF
- Zahlmann G
- Garcia J
- Vassal G
- Grill J
- Morgan PS
- Jaspan T
Grupos
Abstract
The HERBY trial evaluated the benefit of the addition of the antiangiogenic agent Bevacizumab (BEV) to radiotherapy/Temozolomide (RT/TMZ) in pediatric patients with newly diagnosed non-brainstem high-grade glioma (HGG). The work presented here aims to correlate imaging characteristics and outcome measures with pathological and molecular data.
Datos de la publicación
- ISSN/ISSNe:
- 1078-0432, 1557-3265
- Tipo:
- Article
- Páginas:
- 1856-1865
- PubMed:
- 31924736
- Factor de Impacto:
- 5,427 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
CLINICAL CANCER RESEARCH AMER ASSOC CANCER RESEARCH
Citas Recibidas en Web of Science: 14
Documentos
- No hay documentos
Portal de investigación